Zoetis Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This filing reports full-year results; the provided text does not present standalone fourth-quarter financial results.
Business context
Zoetis is a global animal-health company developing and selling medicines, vaccines, diagnostics, and related technologies across companion animals and livestock. It reports two geographic segments: U.S. and International. Companion-animal products accounted for $3.652 billion of revenue and livestock products for $2.940 billion; contract manufacturing and human-health products contributed $83 million.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $6.675 billion | $6.260 billion | +7% reported; +9% operational |
| Net income attributable to Zoetis | $1.638 billion | $1.500 billion | +9% |
| Diluted EPS | $3.42 | $3.11 | +10% |
| Adjusted net income (non-GAAP) | $1.844 billion | $1.755 billion | +5% |
| Adjusted diluted EPS (non-GAAP) | $3.85 | $3.64 | +6% |
| Operating cash flow | $2.126 billion | $1.795 billion | +18% |
| Capital expenditures | $453 million | $460 million | −2% |
Revenue growth reflected approximately 3% volume growth from new products, 3% from in-line products, 2% price growth, and 1% contribution from recent acquisitions. Cost of sales declined to 31% of revenue from 32%; income before taxes was $1.996 billion, or 30% of revenue. The effective tax rate rose to 18.0% from 16.7%. Operating cash flow less capital expenditures was approximately $1.67 billion.
- By segment: U.S. revenue was $3.557 billion, up 11%; International revenue was $3.035 billion, up 2% reported and 7% operational, with foreign exchange reducing reported revenue by about $130 million.
- By species: Companion-animal revenue grew 16% to $3.652 billion, while livestock revenue declined 3% to $2.940 billion. U.S. livestock sales were affected by COVID-related food-supply disruption and weak cattle conditions; international livestock growth in swine and fish partly offset declines elsewhere.
- Liquidity: Cash and equivalents were $3.604 billion, working capital was $4.441 billion, and the current ratio was 3.05:1 at year-end. Cash increased $1.670 billion during the year.
- Debt: Principal debt outstanding was $7.250 billion, versus $6.500 billion in 2019; cash exceeded short-term borrowings. The company issued $1.25 billion of notes in 2020, including 2.00% notes due 2030 and 3.00% notes due 2050, and repaid $500 million of notes due 2020. The $1.0 billion revolving credit facility was undrawn, and the company reported compliance with its financial covenants.
Material changes and notable items
- Companion-animal growth was led by parasiticides and dermatology, including the Simparica franchise, Apoquel, and Cytopoint. Diagnostics and acquisitions also contributed.
- International reported revenue was reduced by currency weakness, particularly in the Brazilian real, Argentine peso, Mexican peso, and Turkish lira.
- Zoetis acquired Fish Vet Group, Virtual Recall, Performance Livestock Analytics, and Ethos Diagnostic Science during 2020; the filing says these acquisitions did not significantly affect consolidated financial statements.
- Other income/deductions shifted from $57 million of income in 2019 to $17 million of deductions in 2020, including impairment charges and increased foreign-currency losses. Certain significant items included $37 million of asset impairment charges, primarily involving precision livestock farming and aquatic-health assets.
- Share repurchases were suspended beginning in the second quarter of 2020 and resumed in January 2021. The 2020 declared dividend was $0.85 per share, compared with $0.692 in 2019.
Outlook, risks, and contingencies
The company discusses 2021 financial guidance in its forward-looking-statement disclosures, but the supplied filing text does not provide clear numerical guidance. Management said COVID-19 would likely continue affecting the business in 2021, while noting uncertainty around customer demand, supply chains, workforce availability, and product approvals. Operations in research, manufacturing, and supply chain continued as essential activities.
- Competition and patents: Generic tulathromycin products were already sold in several markets, and U.S. entry was expected in 2021 following expiration of the U.S. Draxxin formulation patent in February 2021. Several other established product lines also face generic competition or upcoming patent expirations.
- Product concentration: The top five product lines contributed approximately 31% of revenue; the top ten contributed 44%. Apoquel alone represented about 10% and Simparica/Simparica Trio about 6%.
- Industry and operating risks: Key exposures include product safety or quality issues, manufacturing and supplier disruptions, customer and distributor consolidation, changing veterinary and online sales channels, animal-disease outbreaks, foreign exchange, and restrictions or consumer preferences affecting livestock antibacterials. Livestock antibacterials generated approximately $1.1 billion of 2020 revenue.
- Regulatory disclosure: After acquiring Platinum Performance, Zoetis identified transactions potentially involving Iranian residents or entities that may have violated U.S. sanctions rules. It submitted a final voluntary disclosure to OFAC and the Department of Justice in December 2020; the filing does not state an outcome or financial resolution.
- Legal and environmental matters: Management stated that pending proceedings were not expected to have a material adverse effect on the consolidated financial position, but an unfavorable outcome could affect results or cash flows. It could not estimate reasonably possible losses beyond accruals. Environmental expenditures in 2020 included approximately $4 million of capital expenditures and $18 million of other expenditures.
- Tax and interest-rate exposure: Gross unrecognized tax benefits were $188 million at year-end. The company also disclosed LIBOR transition exposure; a 100-basis-point increase in LIBOR-based rates was estimated to increase annual interest expense by approximately $4.5 million.
The independent auditor issued an unqualified opinion on the financial statements and on the effectiveness of internal control over financial reporting as of December 31, 2020.
Important facts for investors to verify
- 2021 guidance and subsequent results, particularly the persistence of COVID-related effects and the pace of companion-animal and livestock demand recovery.
- The effect of generic competition on Draxxin and other concentrated, high-revenue product lines.
- Debt repayment and refinancing plans, including the $600 million of principal due in 2021, and cash generation relative to dividends and repurchases.
- The status and potential consequences of the Platinum-related sanctions disclosure and other material legal, environmental, and tax matters.
- Whether acquisitions and investments in diagnostics, digital tools, and precision livestock farming deliver expected growth, and whether disclosed impairments signal further execution or valuation risks.